Cigna subsidiary Evernorth Health Services will automate prior authorizations for GLP-1 weight-loss drugs under a new program ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

Cigna’s Evernorth has reached new deals with manufacturers Eli Lilly and Novo Nordisk to cap patients’ copays for pricey GLP-1 weight loss medications, the health services business announced ...

Getting access to popular weight loss drugs will be simpler and cheaper for some.Health insurer Cigna (CI) announced a new ...

Morgan Stanley also reaffirmed an Overweight rating with a price target of $1,133, following a new agreement with Cigna/Evernorth to cap patient copays for Eli Lilly’s Zepbound.

Evernorth, the pharmacy benefits unit for health insurer giant Cigna, has reached a deal with drugmakers Novo Nordisk and Eli Lilly to cap the out-of-pocket cost ... patients’ monthly copay costs for ...

Cigna’s (NYSE:CI) health services arm, Evernorth, has launched a pharmacy benefit program that caps out-of-pocket costs at $200 per month for patients using the weight-loss drugs - Wegovy from Novo ...

Cigna’s (NYSE:CI) health services arm, Evernorth, has launched a pharmacy ... Zepbound. The monthly copay for GLP-1 weight loss medicines will be limited to no more than $200 under the new ...

The Cigna Group (NYSE: CI )’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit ...